Janux Therapeutics, Inc. (JANX)

Janux Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-114.48	-113.63	-68.99	-58.29	-63.06	-32.67
Depreciation & Amortization	1.98	2.03	2.06	1.96	0.84	0.11
Stock-Based Compensation	38.79	40.22	33.02	20.01	17.2	6.91
Other Adjustments	-15.98	-17.57	-10.59	-7.69	-2.18	-0.17
Change in Receivables	-35	-	-	-	-	8
Changes in Accounts Payable	1	0.98	1.58	0.28	-0.29	2.14
Changes in Accrued Expenses	2.53	6.29	4.43	-0.68	4.16	3.03
Changes in Unearned Revenue	46.27	-	-1.71	-5.92	1.76	-2.14
Changes in Other Operating Activities	-2.66	-0.55	-3.62	-0.23	-1.35	-2.19
Operating Cash Flow	-77.55	-82.24	-43.81	-50.58	-42.92	-16.98
Capital Expenditures	-0.95	-1.04	-0.36	-1.85	-6.45	-1.48
Purchases of Investments	-446.68	-705.22	-470.58	-317.34	-294.39	-473.63
Proceeds from Sale of Investments	495.32	405.28	212.92	278	359.1	134.15
Investing Cash Flow	47.7	-300.98	-258.02	-41.19	58.27	-340.96
Issuance of Common Stock	7.94	4.95	713.24	59.55	0.5	205.98
Net Common Stock Issued (Repurchased)	7.94	4.95	713.24	59.55	0.5	205.98
Issuance of Preferred Stock	-	-	-	-	-	180.55
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	180.55
Financing Cash Flow	7.94	4.95	713.24	59.55	0.5	386.52
Net Cash Flow	-21.92	-378.27	411.4	-32.22	15.84	28.59
Free Cash Flow	-78.49	-83.28	-44.17	-52.43	-49.37	-18.46
FCF Margin	-571.57%	-832.78%	-417.20%	-648.58%	-573.24%	-507.51%
Free Cash Flow Per Share	-1.26	-1.34	-0.82	-1.19	-1.19	-0.78
Levered Free Cash Flow	-66.3	-105.93	-66.61	-64.74	-64.39	-33.2
Unlevered Free Cash Flow	-108.81	-149.97	-96.46	-79.43	-68.42	-33.46

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q